orkshop Inflammation and chronic hepatitis/hiv infections: who is the driver? Scientific Programme

Scientific Programme orkshop Scientific Coordinators A. d Arminio Monforte (Milan, I) C.F. Perno (Rome, I) M. Puoti (Milan, I) Inflammation and chronic hepatitis/hiv infections: who is the driver? Milan, Italy Palazzo delle Stelline January 30-31, 2014

orkshop Inflammation and chronic hepatitis/hiv infections: who is the driver? Endorsements Ministero della Salute Istituto Superiore di Sanità Agenzia Italiana del Farmaco Regione Lombardia Provincia di Milano Comune di Milano Università degli Studi, Milan Dipartimento di Scienze della Salute, Università degli Studi, Milan Università degli Studi Tor Vergata, Rome Azienda Ospedaliera San Paolo - Polo Universitario, Milan Azienda Ospedaliera Niguarda Ca' Granda, Milan Fondazione Policlinico Tor Vergata, Rome SIV, Società Italiana di Virologia SIVIM, Società Italiana di Virologia Medica AISF, Associazione Italiana per lo Studio del Fegato AMCLI, Associazione Microbiologi Clinici Italiani Fondazione AVIRALIA Fondazione ICONA ANLAIDS, Associazione Nazionale per la lotta contro l'aids LILA, Lega Italiana per la lotta contro l'aids Associazione NADIR NPS Italia, Network Persone Sieropositive Honorary President Mauro Moroni Professor Emeritus, University of Milan I Scientific Coordinators Antonella d Arminio Monforte San Paolo Hospital, University of Milan I Carlo Federico Perno University of Tor Vergata, Rome I Massimo Puoti Niguarda Ca Granda Hospital, Milan I Scientific Committee Massimo Andreoni University of Tor Vergata, Rome I Mario Angelico University of Tor Vergata, Rome I Andrea Antinori IRCCS - INMI Lazzaro Spallanzani, Rome I Savino Bruno Fatebenefratelli Hospital, University Milan Bicocca, Milan I Mario Clerici Don C. Gnocchi Foundation, University of Milan I Massimo Colombo Foundation IRCCS Maggiore Hospital, University of Milan I Andrea Cossarizza University of Modena and Reggio Emilia, Modena I Andrea De Maria University of Genoa, IRCCS AOU San Martino - IST Genoa I Massimo Galli Luigi Sacco Hospital, University of Milan I Andrea Gori San Gerardo Hospital, Monza I Adriano Lazzarin University Vita-Salute San Raffaele, Milan I Alberto Mantovani Humanitas Clinical Institute, University of Milan I Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I Mario Strazzabosco University Milan Bicocca, Milan I Massimo Zuin San Paolo Hospital, University of Milan I Scientific Secretariat Giulia Marchetti San Paolo Hospital, University of Milan I Roberto Rossotti Niguarda Ca Granda Hospital, Milan I Valentina Svicher University of Tor Vergata, Rome I 2

Faculty Massimo Andreoni University of Tor Vergata, Rome I Gioacchino Angarano University Hospital of Bari I Mario Angelico University of Tor Vergata, Rome I Andrea Antinori IRCCS - INMI Lazzaro Spallanzani, Rome I Guido Antonelli University Hospital Umberto I and Sapienza University, Rome I Alessandra Bandera San Gerardo Hospital, Monza I Raffaele Bruno University of Pavia I Savino Bruno Fatebenefratelli Hospital, University Milan Bicocca, Milan I Giampiero Carosi Professor Emeritus, University of Brescia I Antonella Castagna San Raffaele Scientific Institute, Milan I Francesca Ceccherini-Silberstein University of Tor Vergata, Rome I Antonella Cingolani Catholic University, Rome I Mario Clerici Don C. Gnocchi Foundation, University of Milan I Massimo Colombo Foundation IRCCS Maggiore Hospital, University of Milan I Antonio Craxì Paolo Giaccone Hospital, Palermo I Antonella d Arminio Monforte San Paolo Hospital, University of Milan I Gabriella d Ettorre University Hospital Umberto I, Rome I Andrea De Luca Siena University Hospital, Siena I Andrea De Maria University of Genoa, IRCCS AOU San Martino - IST Genoa I Daniel C. Douek Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda USA Carlo Ferrari University Hospital of Parma I Giovanni Battista Gaeta Second University of Naples I Massimo Galli Luigi Sacco Hospital, University of Milan I Antonio Gasbarrini Catholic University, Gemelli Hospital, Rome I Nicola Gianotti San Raffaele Scientific Institute, Milan I Enrico Girardi IRCCS - INMI Lazzaro Spallanzani, Rome I Andrea Gori San Gerardo Hospital, Monza I Peter Hunt University of California, San Francisco USA Giuseppe Ippolito IRCCS - INMI Lazzaro Spallanzani, Rome I Christine Katlama University Pierre et Marie Curie, Pitié- Salpétrière Hospital, Paris F Alan L. Landay Rush University, Chicago USA Adriano Lazzarin University Vita-Salute San Raffaele, Milan I Michael M. Lederman Case Western Reserve University School of Medicine, University Hospitals/Case Medical Center, Cleveland USA Massimo Levrero Sapienza University, Rome I Miriam Lichtner Sapienza University of Rome, Polo Pontino, Latina I Alberto Mantovani Humanitas Clinical Institute, University of Milan I Giulia Marchetti San Paolo Hospital, University of Milan I Fabio Marra University of Florence I Claudio Maria Mastroianni Sapienza University of Rome, Polo Pontino, Latina I Gabriele Missale University Hospital of Parma I Mario Umberto Mondelli University of Pavia, Foundation IRCCS San Matteo General Hospital, Pavia I Mauro Moroni Professor Emeritus, University of Milan I Carlo Federico Perno University of Tor Vergata, Rome I Massimo Pinzani Institute for Liver and Digestive Health, University College London, Royal Free Hospital, London UK Massimo Puoti Niguarda Ca Granda Hospital, Milan I Giovanni Raimondo University Hospital of Messina I Agostino Riva Luigi Sacco Hospital, University of Milan I Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I Jürgen Rockstroh University of Bonn D Roberto Rossotti Niguarda Ca Granda Hospital, Milan I Christine Rouzioux Necker Hospital, University Paris Descartes, Paris F Stefano Rusconi Luigi Sacco Hospital, University of Milan I Caroline Sabin University College London UK Andrea Savarino Istituto Superiore di Sanità, Rome I Guido Silvestri Emory University School of Medicine, Yerkes National Primate Research Center, Atlanta USA Mario Strazzabosco University Milan Bicocca, Milan I Valentina Svicher University of Tor Vergata, Rome I Gloria Taliani Sapienza University, Rome I Giuseppe Tambussi San Raffaele Scientific Institute, Milan I Luca Valenti Foundation IRCCS Ca Granda General Hospital, University of Milan I 3

orkshop Inflammation and chronic hepatitis/hiv infections: who is the driver? Scientific Programme January 30, 2014 10.30-10.45 Welcome Addresses M. Moroni 10.45-11.00 Rationale and presentation of the Workshop A. d Arminio Monforte, C.F. Perno, M. Puoti 11.00-11.45 OPENING LECTURE Conveners M. Andreoni, L. Valenti 11.00-11.30 Inflammation and chronic viral infections A. Mantovani 11.30-11.45 Discussion A. De Maria 11.45-13.00 SESSION 1 What is the role of inflammation in the different scenarios of persistent hepatitis virus infections Conveners M. Clerici, V. Svicher 11.45-12.00 Role of the cell-mediated immune response in liver damage and viral persistence in HBV infection C. Ferrari 12.00-12.05 Q & A 12.05-12.20 HCV and the host inflammatory response M.U. Mondelli 12.20-12.25 Q & A 12.25-12.40 HBV and HCV in the setting of HIV-related immune impairment R. Bruno 12.40-12.45 Q & A 12.45-13.00 Discussion S. Bruno 13.00-14.00 Lunch and poster discussion 14.00-15.15 SESSION 2 HIV vs inflammation: who drives what Conveners A. Gori, G. Marchetti 14.00-14.15 HIV and inflammation: what can we learn from animal models? G. Silvestri 14.15-14.20 Q & A 14.20-14.35 Viral replication as driver of inflammation? P. Hunt 14.35-14.40 Q & A 14.40-14.55 Inflammation as driver of viral replication? A.L. Landay 14.55-15.00 Q & A 15.00-15.15 Discussion A. Savarino 15.15-16.00 LECTURE Conveners G. Carosi, G.B. Gaeta 15.15-15.45 Pathogenesis of liver fibrosis in the setting of chronic hepatitis C M. Pinzani 15.45-16.00 Discussion M. Angelico 16.00-16.15 Coffee break 4

January 30, 2014 16.15-17.15 SESSION 3 Oral presentations based on selected abstracts Conveners G. Marchetti, R. Rossotti, V. Svicher Discussants A. Bandera, S. Rusconi HIV-Envelope Protein Gp120 Actives the Nalp3-Inflammasome Through the Engagement of CCR5 Receptor in Human Hepatic Stellate Cells A. Cappon*, R. Bruno**, S. Gessani***, A. Masotti, and F. Marra *University of Florence, Florence, Italy, **IRCCS, University of Pavia, Pavia, Italy, ***Istituto Superiore di Sanità, Rome, Italy, Ospedale Pediatrico Bambino Gesù, Rome, Italy Strong antiviral activity of thiazolides against HIV-1BaL infection in vitro F. Gnudi*, M. Biasin*, D. Trabattoni*, M. De Luca*, S.V. Ibba*, I. Saulle*, M. Fiocchi*, J.F. Rossignol**, M. Clerici* *Chair of Immunology, University of Milan, Italy, **The Glycobiology Institute, Department of Biochemistry, University of Oxford, UK IFN and bacterial TLR ligands act synergistically to increase production of CXCL10 from hepatocytes M. Crane*,**, S. Tennakoon*,**, B. Sebolao*,**, D. Iser*,**,***, S.R. Lewin*,** *Alfred Hospital, Monash University, Melbourne, Australia **Burnet Institute, Melbourne, Australia ***St Vincent s Hospital, Melbourne, Australia Monocyte and Dendritic cell subsets, inflammatory and fibrotic soluble markers in HCV monoinfected and HCV/HIV coinfected subjects: the effect of anti-hcv therapy M. Lichtner*, S. Savinelli**, C. Mascia**, T. Tieghi*, R. Marocco*, P. Zuccalà**, A. Ermocida**, S. Vita, F. Mengoni**, G.M. Liuzzi***, T. Latronico***, C.M. Mastroianni*, V. Vullo** *Infectious Diseases Unit, Sapienza University, Latina, **Public Health and Infectious Diseases, Sapienza University, Rome, Italy ***Biosciences, Biotechnology and Biofarmaceutics, University of Bari, Bari Sapienza University of Rome, Cenci Bolognetti Foundation Pharmacologically Induced Functional Cure-like Condition in Chronically SIVmac251-Infected Macaques is Associated with Decreased Levels of Immune Activation in T-cells I.L. Shytaj*, R. Pal**, M.G. Ferrari**, J. Livesay**, M.G. Lewis***, E. Garaci and A. Savarino* *Istituto Superiore di Sanità, Rome, Italy **ABL, Rockville, Maryland, USA ***BIOQUAL, Inc. Rockville, Maryland, USA Dept. of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy Inherent and HCV-dependent regulation of NK cell receptors: NKp30, DNAM-1, CD85j in pegifn -Ribavirin treated patients with diverging clinical courses F. Bozzano*, A. Picciotto*, P. Costa*, F. Marras**, V. Fazio*, S. Marenco*, I. Hirsch***, D. Olive***, L. Moretta**, A. De Maria*, *Università di Genova, Italy, **Istituto G. Gaslini, Genova, Italy, ***Institute Paoli Calmettes, IFR 137, INSERM, Marseilles, France, S.S. Infettivologia, IRCCS San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy 17.15-18.10 SESSION 4 Microbial translocation and inflammation Conveners M. Galli, M. Strazzabosco 17.15-17.30 Inhibition of inflammation during acute SIV infection D.C. Douek 17.30-17.35 Q & A 17.35-17.50 Microbial translocation and inflammation in HBV- and HCV- mediated cirrhosis A. Gasbarrini 17.50-17.55 Q & A 17.55-18.10 Discussion G. Tambussi 18.10-18.55 LECTURE Convener G. Angarano 18.10-18.40 Clinical and immunological correlates of spontaneous control of HIV infection C. Katlama 18.40-18.55 Discussion N. Gianotti 5

orkshop Inflammation and chronic hepatitis/hiv infections: who is the driver? Scientific Programme January 31, 2014 09.00-10.35 SESSION 5 Immune activation and clinical outcome: what role and what clinical marker Conveners A. Lazzarin, G. Missale 09.00-09.15 Drivers and outcomes of inflammation in HIV infection M.M. Lederman 09.15-09.20 Q & A 09.20-09.35 Markers of inflammation and fibrosis in the clinics: HCV and HBV F. Marra 09.35-09.40 Q & A 09.40-09.55 How to track HIV reservoirs in the clinics? C. Rouzioux 09.55-10.00 Q & A 10.00-10.15 How to track hidden virus in the clinics: HCV and HBV G. Taliani 10.15-10.20 Q & A 10.20-10.35 Discussion F. Ceccherini-Silberstein 10.35-10.50 Coffee break 10.50-12.25 SESSION 6 Interplay between immune activation/inflammation and clinical progression of HIV-, HBV- and HCV- related diseases: what space for therapy interventions Conveners C.M. Mastroianni, G. Rizzardini 10.50-11.05 Control of inflammation: is cart enough? A. Antinori 11.05-11.10 Q & A 11.10-11.25 Is control of inflammation sufficient in the prevention of HBV- related disease? G. Raimondo 11.25-11.30 Q & A 11.30-11.45 Control of HIV: which impact does it have on liver disease progression in hepatitis coinfection? J. Rockstroh 11.45-11.50 Q & A 11.50-12.05 Does HCV eradication halt inflammation and affect fibrosis in chronic hepatitis C? A. Craxì 12.05-12.10 Q & A 12.10-12.25 Discussion A. Castagna 12.25-13.25 SESSION 7 Oral presentations based on selected abstracts Conveners G. d Ettorre, E. Girardi, M. Lichtner Discussants A. Cingolani, A. Riva Targeting Gut Mucosa in HIV+ Subjects With Prebiotics and Glutamine: A Clinical Trial S. Serrano-Villar 1, J. Vázquez 2, N. Madrid 1, A. Vallejo 1, J. Martínez-Botas 3, T. Sainz 4, M. Vera 5, C. Rodríguez 5, J. Del Romero 5, S. Ferrando-Martínez 6, F. Dronda 1, M. Coronel 1, E. Domínguez 1, A. Latorre 2, M.J. Gosalbes 2, A. Moya 2, S. Moreno 1, V. Estrada 6, Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, University Hospital Virgen 6

January 31, 2014 del Rocío, Sevilla 7, HIV Unit, Department of Internal Medicine, University Hospital Clínico San Carlos, 28040 Madrid, Spain 1 Hospital Universitario Ramón y Cajal, Madrid, 2 Centro Superior de Investigación en Salud Pública, Valencia, y CIBEResp, Instituto de Salud Carlos III, Madrid, 3 Hospital Universitario Ramón y Cajal, Madrid y CIBEResp, Instituto de Salud Carlos III, Madrid, 4 Hospital Universitario Gregorio Marañón, 5 Centro Sandoval, Madrid, 6 Hospital Virgen del Rocío, Sevilla, 7 Hospital Universitario Clínico San Carlos, Madrid Bone Marrow CD34+ Progenitors Cells Harbor HIV Genomes and HIV-DNA is Correlated to Plasma HIV-RNA V. Bordoni, I. Abbate, D. Viola, G. Rozera, M. Bibas, A. Ammassari, C. Agrati, A. Rinaldi, M. Capobianchi, F. Martini National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Rome Italy sepcr as Inflammatory Biomarker in Naïves Chronic HIV-Infected Patients after the beginning of Anti-Retroviral Therapy S. Chiappetta*, M. Ripa*, M. Pogliaghi*, V. Longo**, C. Razzari***, P. Cinque**, E. Faioni***, S. Nozza**, A. Lazzarin**, G. Tambussi** *Università Vita- Salute San Raffaele, Milan, Italy; **San Raffaele Scientific Institute, Milan, Italy; ***Università degli Studi di Milano, Milan, Italy CD8+CD28-CD127loCFD39+ Treg: a new biomarker for HIV disease progression? A. Parodi*, C. Dentone**, F. Kalli*, A. Di Biagio***, P. Fraccaro*, G. Orofino, G. Cenderello, M. Giacomini*, D. Fenoglio* and G. Filaci* *University of Genoa, Genoa, Italy, **Sanremo Hospital, Sanremo, Italy, ***IRCSS AOU San Martino Hospital-IST, Genoa, Italy, Amedeo di Savoia Hospital, Turin, Italy, Galliera Hospital, Genoa, Italy Chronic inflammation in a long term cohort of HIV infected patients according to the normalization of CD4:CD8 ratio under ART G. Bruno*, A. Saracino*, L. Scudeller**, A. Volpe*, G. Punzi*, A. Lagioia*, N. Ladisa*, L. Monno*, G. Angarano* *Clinic of Infectious Diseases, University of Bari **IRCCS San Matteo, Pavia, Italy cart Intensification Results in Better Anti-HCV Treatment Response in HCV/HIV Co-infected Patients A. Uglietti, A. De Bona, M. Cerrone, E. Merlini, G. Marchetti and A. d Arminio Monforte San Paolo Hospital, Milan, Italy 13.25-14.10 Lunch and poster discussion 14.10-15.25 SESSION 8 The role of drugs in preventing cancer Conveners G. Antonelli, G. Ippolito 14.10-14.25 Targeting the inflammation by virus eradication in the prevention of HCV associated hepatocellular carcinoma M. Colombo 14.25-14.30 Q & A 14.30-14.45 Interplay between HBV and inflammatory host factors in the pathway towards liver cancer M. Levrero 14.45-14.50 Q & A 14.50-15.05 Impact of ART in non-aids related cancers C. Sabin 15.05-15.10 Q & A 15.10-15.25 Discussion A. De Luca 15.25-15.40 Awards Ceremony G. Antonelli, G. Marchetti, R. Rossotti, V. Svicher 15.40-16.10 Closing remarks A. d Arminio Monforte, C.F. Perno, M. Puoti 7

Optimizing treatment in HIV 1 1. Linee Guida Italiane sull utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1; Luglio 2012 http://www.salute.gov.it/imgs/c_17_pubblicazioni_1301_allegato.pdf

Selected Posters 1. Innate immunity cell activation in virologically suppressed HIV infected Maraviroc treated patients C. Dentone 1,2, A. Di Biagio 3, A. Parodi 2, F. Bozzano 4, P. Fraccaro 5, A. Signori 6, G. Cenderello 7, G. Orofino 8, M. Guerra 9, G. Ferrea 1, C. Viscoli 3,10, M. Giacomini 2,5, A. De Maria 2,10, G. Filaci 2,11, D. Fenoglio 2,11 1 Sanremo Hospital, Center of Excellence for Biomedical Research (CEBR), 2 University of Genoa, 3 IRCCS San Martino Hospital, Genoa, DIMES Dept of Experimental Medicine, 4 University of Genoa, Department of Informatics, Bioengineering, Robotic and System Engineering (DIBRIS), 5 University of Genoa, Dept of Health Sciences (DISSAL)-Section of Biostatistics, 6 University of Genoa, 7 Galliera Hospital, Genoa, 8 Amedeo di Savoia Hospital,Turin, 9 La Spezia Hospital, 10 DISSAL University of Genoa, 11 Dept of Internal Medicine (DIMI), University of Genoa 2. Asymptomatic HIV Patients: Dysfunctions on Biochemical and Immunological Tests, According to Different Therapeutic Responses K.I. Tasca*, M. Gatto*, C.C. Camargo*, A.A. Tanikaw a*, J.E. Corrente*, F.H. Aoki**, L.R. Souza* *Botucatu Medical School, Univ Estadual Paulista (UNESP), Botucatu, Brazil; **University of Campinas (UNICAMP), Campinas, Brazil 3. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection I. Saulle*, M. Biasin*, M. Sironi**, R. Cagliani**, F. Gnudi*, S. Ibba*, G. Filippi***, S. Yahyaei*, C. Tresoldi**, S. Riva**, D. Trabattoni*, L. De Gioia***, S. Lo Caputo, F. Mazzotta, D. Forni*, C. Pontremoli*, J.A. Pineda, U. Pozzoli**, A. Rivero-Juarez, A. Caruz^, M. Clerici^^-^^^ *Scientific Institute IRCCS E. MEDEA, Bioinformatics, Bosisio Parini, Italy; **Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; ***Department of Biotechnology and Biosciences, University of Milan-Bicocca, Milan, Italy; S. Maria Annunziata Hospital, Florence, Italy; Infectious Diseases and Microbiology Clinical Unit. Valme Hospital, Seville, Spain; Maimonides Institut for Biomedical Research (IMIBIC)-Reina Sofia Universitary Hospital-University of Cordoba, Spain; ^Immunogenetics Unit, Department of Experimental Biology, University of Jaen, Jaen, Spain; ^^Chair of Immunology, Department of Physiopathology and Transplantation, University of Milan, Milan, Italy; ^^^Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy 4. Does HIV-1 Co-receptor Tropism correlate with fibrosis progression in HIV/HCV co-infected patients? G. Bruno, A. Saracino, L. Scudeller, G. Punzi, A. Lagioia, N. Ladisa, L. Monno and G. Angarano Clinic of Infectious Diseases, University of Bari; Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia, Italy 5. Effects of Dietary Supplementation with Probiotics in HIV-1 Infected Patients N. Giustini, S. Serafino, S. Marcellini, E. Nelson Cavallari, V. Bellelli, P. Vittozzi, T. Ascoli Bartoli, S. Gebremeskel, L. Bianchi, G. Ceccarelli, G. d Ettorre, V. Vullo "Sapienza" University of Rome, Italy 6. Is Residual Viremia a Trigger of Immune Activation in HIV-1 Infected Subjects? S. Serafino, N. Giustini, F. Falasca, P. Maida, V. Bellelli, F. Tierno, L. Bianchi, G. Ceccarelli, O. Turriziani, G. d Ettorre, G. Antonelli, V. Vullo "Sapienza" University of Rome, Italy 7. Non-cirrhotic Portal Hypertension in three HIV-seropositive Women: when Ultrasound Matters M.T. Giordani*, V. Manfrin*, E. Brunetti**, D. Danieli***, F. Rinaldi** *Infectious and Tropical Diseases Unit, San Bortolo Hospital, Vicenza, Italy, **Department of Infectious Diseases, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, ***Pathology Service, San Bortolo Hospital, Vicenza, Italy 8. Moderate physical activity improves soluble and cell markers of inflammation in cart-treated patients V. Longo*, M. Bonato**, L. Galli*, S. Bossolasco*, G. Pavei**, L. Passeri*, G. Merati**, A. Lazzarin*, A. La Torre**, P. Cinque* *San Raffaele Scientific Institute, Milano, ITALY **Università degli Studi di Milano, Milano, Italy 9. Anti-HCV Treatment-Associated T Cell Subsets Changes in HIV-HCV Coinfected Patients on Effective HAART A. De Bona*, A. Uglietti*, M. Cerrone*, F. Bai*, G. Carpani**, E. Senigaglia**, G. Marchetti*, A. d Arminio Monforte* *Clinic of Infectious Diseases, San Paolo Hospital-University of Milan, Italy **Transfusional Center, San Paolo Hospital- University of Milan, Italy 9

General information Congress web site www.inflammation2014.com Workshop Venue Palazzo delle Stelline Corso Magenta, 61-20123 Milan, Italy www.stelline.it CME Provider and Organizing Secretariat Effetti srl Via Gallarate, 106-20151 Milan, Italy Ph. +39 02 3343281 - Fax +39 02 33496370 - inflammation2014@effetti.it Official language English. No simultaneous translation provided orkshop Inflammation and chronic hepatitis/hiv infections: who is the driver? CME accreditation The Workshop has obtained 7 CME credits (ID number 150-77648) from Italian Health Ministry for the following professionals: Medical Doctor, Biologist, Territory and Hospital Pharmacist, Nurse, Medical Laboratory Technician and Psychologist. Medical specialties include: Infectious and Tropical Diseases, Hygiene, Epidemiology and Public Health, Microbiology and Virology, Allergology and Clinical Immunology, Internal Medicine and Gastroenterology. Credits will be given only if a participant attends 100% of the teaching event and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. Participants are also required to wear the identification badge during working sessions, to provide their signature for attendance tracking purposes and to complete the satisfaction questionnaire. Poster session Authors may post up their posters subject to registration. The selected posters should be affixed in the foyer outside Sala Volta (1st floor), one hour before the beginning of the Workshop and taken away at the end of the scientific works. Posters should be prepared in English. During poster discussion, authors are kindly requested to remain at disposal near their own poster for discussion or questions to be asked by conference participants. Cyber point A Cyber point is available at exhibition area in the foyer outside Sala Volta (1st floor). Slide center A slide center will be available to speakers, with computers, CD writer, printer and technical support. Only Powerpoint slide presentations will be accepted. If a special equipment is needed, this should be communicated in advance to the Organizing Secretariat. Slides must be submitted 2 hours before the scheduled presentation. Technical equipment Congress room is suitable for Powerpoint presentations and equipped with computers and overhead projectors. Speakers may not use their own computers for their presentations. Exhibition area A technical-pharmaceutical and scientific publishing exhibition area will be open from Thursday January 30 th at 10:30 a.m. to Friday January 31 st at 04:30 p.m. Web repository Abstracts (oral and poster) and slide presentations of any authors who provide its consent to publication will be published on Workshop web site (www.inflammation2014.com) at the end of the event. Congress Abstracts Scan the Qr-code image with your mobile device or visit www.inflammation2014.com/abstract/ to reach Workshop Abstracts 11

The Chairmen, the Scientific Secretariat and the Provider wish to thank for support given in the form of unrestricted educational grants and the following Companies: PLATINUM SPONSOR GOLD SPONSORS OTHER SPONSORS Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd has had no input into the content of the materials and presentations used at this event.